Archives

Abstract Number: 1026 – First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Presenter: Hang Quach, MD, FRACP, FRCPA, MBBSSession: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple MyelomaDate & Time: Monday, December 9, 2024 5:45 PM–6:00 PMLocation: Hall B (San Diego Convention...

Abstract Number: 1025 – Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Presenter: Irwindeep Sandhu, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple MyelomaDate & Time: Monday, December 9, 2024 5:30 PM–5:45 PMLocation: Hall B (San Diego Convention Center)Keywords:...

Abstract Number: 1024 – Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Presenter: Michael H. TomassonSession: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple MyelomaDate & Time: Monday, December 9, 2024 5:15 PM–5:30 PMLocation: Hall B (San Diego Convention Center)Keywords:...

Abstract Number: 1023 – Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Presenter: Emma Searle, MD, PhDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple MyelomaDate & Time: Monday, December 9, 2024 5:00 PM–5:15 PMLocation: Hall B (San Diego Convention Center)Keywords:...

Abstract Number: 1022 – Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light–‘Chain (AL) Amyloidosis

Presenter: Sikander Ailawadhi, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple MyelomaDate & Time: Monday, December 9, 2024 4:45 PM–5:00 PMLocation: Hall B (San Diego Convention Center)Keywords:...

« Older Entries

Next Entries »

Abstract Number: 1026 – First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Abstract Number: 1025 – Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Abstract Number: 1024 – Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Abstract Number: 1023 – Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Abstract Number: 1022 – Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light–‘Chain (AL) Amyloidosis

Recent Posts

Recent Comments

Categories

Meta